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Abstract 
The orexin receptors are peptide-sensing G 
protein-coupled receptors that are intimately 
linked with regulation of the sleep/wake cycle. 
We used a recently solved X-ray structure of 
the orexin receptor subtype 2 in computational 
docking calculations with the aim to identify 
additional ligands with unprecedented 
chemotypes. We found validated ligands with 
a high hit rate of 29% out of those tested, none 
of them showing selectivity with respect to the 
orexin receptor subtype 1. Furthermore, of the 
higher-affinity compounds examined, none 
showed any agonist activity. While novel 
chemical structures can thus be found, 
selectivity is a challenge owing to the largely 
identical binding pockets. 
Introduction 
The sleep/wake cycle is one of the 
fundamental features of organisms with a 
central nervous system. Especially in humans, 
it guides our every-day lives and is one of the 
key activities that keep us healthy and sane. 
Both sleep deprivation and the inability to 
sleep (insomnia) are therefore unpleasant for 
an individual and have been shown to have 
harmful physiological effects (1), and 
constitute a huge burden on society as a 
whole. (2) In order to ameliorate insomnia, two 
ways can be envisioned: one is to make the 
brain artificially sleepy; the other is to block 
the signals that mediate wakefulness. While 
more traditional insomnia medications have 
tried to do the former, the latter seems like a 
strategy that should lead to fewer side effects.  
In humans, one of the main pathways to 
transmit wakefulness signals is the orexin 
peptide/orexin receptor system. (3) It consists 
of two peptides, orexin A and orexin B, and 
two G protein-coupled receptors (GPCRs), 
orexin receptor subtype 1 (OX1R) and subtype 
2 (OX2R). The two peptides are 33 and 28 
amino acids in length, respectively, and bind 
with nanomolar affinities to both receptors. At 
the same time, the two receptors are highly 
homologous, with 63% sequence identity, and, 
most importantly, differ by only two amino 
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acid substitutions in the binding pocket. 
Despite this high sequence similarity, orexin A 
achieves a certain amount of selectivity for 
OX1R over OX2R. (4) 
In 2014, the first antagonist of the OX2R, 
suvorexant, obtained regulatory approval as an 
insomnia medication in the US. One year later, 
the crystal structure of this molecule in 
complex with OX2R was published. (5) It 
showed that suvorexant was binding in a 
“horseshoe shape”, which is consistent with 
earlier NMR investigations showing that 
suvorexant was able to adopt such a 
conformation in solution. (6) The receptor was 
confirmed to be a typical GPCR with seven 
membrane-spanning helices. Moreover, the 
crystallographic data demonstrated that 
suvorexant was interacting with the receptor 
mainly through hydrophobic interactions. In 
fact, there are only two polar interactions, one 
a direct hydrogen bond to Asn3246.55, the other 
a water-mediated hydrogen bond with 
His3507.39 (Figure 1). (5) 
Aiming to exploit this structure in an 
unbiased computational screen, we have asked 
three questions. Firstly, could an unbiased 
docking screen and the analysis of the 
predicted binding modes suggest other polar 
interaction possibilities for small molecules in 
the binding pocket? Secondly, could an apolar 
binding pocket as this one be as suitable for 
docking (manifested by high hit rates) as the 
more polar pockets of the aminergic receptors 
investigated earlier. (7,8,9,10,11) Lastly, could 
comparison of our hit molecules with the 
already known chemical space for the orexin 
receptors identify novel chemotypes that might 
present scaffolds worthwhile to elaborate on 
further with medicinal chemistry?  
  
Figure 1: Two-dimensional representation of 
the binding mode of suvorexant (PDB code 
4S0V) generated with the MOE suite. Two 
interactions of suvorexant with OX2R are 
indicated as dashed green lines: An H-bond 
between amide carbonyl and Asn3246.55 and a 
π-π interaction between 5-methyl-2-triazol-
phenyl and His3507.39. 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   











Selection of parent hits: Primary docking 
screen 
Docking of 7.337 million compounds from 
the DrugsNow subset of the ZINC database 
into the OX2R (see Methods for details) and 
subsequent post-processing of its outcome 
resulted in 6500 unique poses, split up in 6000 
from the top ranks of the lists sorted according 
to HYBRID, DSX, or SZYBKI scores and an 
additional 500 from the calculations with 
DOCK. The visual inspection of these poses 
resulted in 85 virtual hit candidates (HYBRID: 
14; DSX: 25; SZYBKI: 14 and DOCK: 32 
poses, respectively [Figure 2]). Forty-three 
compounds were available from their vendors 
and analyzed pharmacologically. These 
compounds will be referred to as the “parent” 
compounds P1-P43 in the following and are 
shown in Table S2, with selected compounds 
also displayed in Figure 4. 
Validation of cell lines and examination of 
primary docking screen  
Pharmacological studies were conducted 
in CHO cells stably expressing the human 
orexin 1 receptor (CHO-OX1) or human orexin 
2 receptor (CHO-OX2). Suvorexant, a known 
dual OX1/OX2 receptor antagonist, inhibited 
the specific binding of both 3H-SB674042 to 
the human OX1R and 
3H-EMPA to the human 
OX2R with high affinity (p Ki 8.51 and 8.53, 
respectively [Table 1]). The known OX1R 
antagonists SB334867 and SB674042 were 
Figure 2: Schematic of the primary docking screen workflow. A: The ZINC DrugsNow subset of 
~7.4 M compounds was subjected to conformer generation used for docking. In addition, ~4 M 
ZINC LeadLike compounds were docked as-is. B: Threefold post-processing of the top 1 % slice 
(6500 poses – 2000 each from HYBRID, DSX, SZYBKI and 500 from DOCK) concluded by 
visual inspection, selection of compounds and their experimental validation. C: Schematic of the 
secondary similarity screen workflow. Eight experimentally validated hits were used as queries 
for a fingerprint-based similarity screen of three 2000 slices from the primary screen. The three 
sets of 30 nearest neighbors each were optimized with SZYBKI and subjected to visual inspection. 
Selected virtual hits were validated experimentally. 
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found to have much higher affinity for the 
CHO-OX1 cells than the CHO-OX2 cells, 
whereas the known OX2R antagonists 
JNJ10397049 and EMPA had much higher 
affinity for the CHO-OX2 cells (Table 1). 
These are consistent with previous values and 
demonstrate the existence of each of the 
receptors in the two respective cell 
lines. (12,13,14) Conversely, in cells not 
transfected with either receptor, no binding of 
3H-SB674042 or 3H-EMPA, respectively, 
could be observed.  
Of the 43 initial compounds identified 
from the primary docking screen, eleven had 
some degree of measurable affinity for either 
the OX1 or OX2 receptor, giving an initial hit 
rate of 26 %. Of these, P33 had the highest 
affinity with a pKi value of 5.54 at the OX2R 
(Figure 3, Table 1, Figure 4, for space 
reasons, all other compounds that are not 
among the ten with the highest affinity are 
depicted in the Supplementary Information 
[Table S 2]). Almost all measured compounds 
did not show selectivity. Five compounds 
showed a very minor degree of selectivity: P34 
had a 5-fold OX2R selectivity (ΔpKi of -0.69), 
P9 and P33 a 4-fold OX2R selectivity (a ΔpKi 
of -0.62 and -0.59, respectively) whilst P12 
and P18 had at least a 3-fold OX1R selectivity. 
Figure 3: Inhibition of A 3H-SB67404 binding to CHO-OX1 cells and B 
3H-EMPA binding to 
CHO-OX2 cells in response to P33, F33.3 and suvorexant. Bars represent total and non-specific 
binding (as determined by 10 μM suvorexant) and data point are mean ± sem of triplicate 
determinations. These experiments are representative of 4 separate experiments. The 
concentration of radioligand in these experiments was A: 1.14 and B: 0.60 nM. 
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Examination of daughter compounds 
Figure 4: The ten compounds with the highest measured affinity in the 3H-EMPA binding assay 
to CHO-OX2 cells identified in this study. P33 and P35 compound families are emphasized with 
a box. 
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For nine parent compounds, daughter 
derivatives (F) were obtained: We selected 
between one (P22 and P31) and 15 (P35) 
daughter molecules from each parent – in total 
54 compounds – based on availability of 
similar compounds and their favorable docking 
scores and poses. The identifiers of the 
daughter compounds in this text are based on 
the ID of the parent compound and the order 
number of each of them, separated by a point. 
E.g. compound F33.1 is the first daughter 
compound of parent P33. Table 2 shows their 
affinities measured against OX1R and OX2R. 
Compound P33 can be considered the most 
fruitful parent compound, as all but one of the 
seven derivatives measured also showed 
measurable affinity against the OX2R. 
Moreover, its daughter F33.3 bound with the 
highest affinity of all ligands, at a pKi of 6.18 
(Ki of 660 nM, Figure 3). In total, 16 of the 54 
derivatives tested bound to the receptor. This 
brings the hit rate of daughter compounds to 
30 %. Finally, to further exclude any non-
orexin receptor mediated effects, the most 
potent ligands were examined for their ability 
to bind to an unrelated receptor, the human β1-
adrenergic receptor. Although the β1-
antagonist CGP20712A inhibited specific 
binding with high affinity, none of the ligands 
with orexin receptor affinity had any detectable 
binding for the β1-adrenergic receptor (see 
supplementary data).  
1.1 Examination of functional responses 
Orexin 1 and 2 receptors are both Gq-
coupled GPCRs and therefore stimulate an 
increase in intracellular calcium release. To 
examine whether the compounds had an 
agonist activity, the ability of some of the 
higher affinity compounds to stimulate 
intracellular calcium release was measured. 
Orexin A stimulated a potent agonist response 
in both the CHO-OX1 cells (pEC50 9.67 ± 0.13, 
19.4 ± 24 fold over basal, 58.8 ± 2.4 % that of 
10 μM ionomycin, n=5) and the CHO-OX2 
cells (pEC50 10.31 ± 0.07, 32.8 ± 4.2 fold over 
Figure 5: Intracellular calcium release in A CHO-OX1 cells and B CHO-OX2 cells in response to 
orexin A, P33 and F33.3. Bars represent basal intracellular calcium release and that in response 
to 10µ M ionomycin alone. Data points are mean ± sem of triplicate determinations and these 
single experiments are representative of 4 separate experiments in each case. 
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basal, 71.8 ± 1.8 % that of 10 μM ionomycin, 
n=6; Figure 5). No agonist response was seen 
in response to any of the other ligands 
examined. Thus, no agonist response was seen 
to parent compounds P9, P33 or P35 or 
daughter compounds F7.3, F33.2, F33.3, 
F33.6, F33.7, or S2.7 (n=3 to 9 for each ligand 
at each receptor; Figure 5). In addition, no 
response was seen to parent compounds P7, 
P21, P22, P27, P32, P34, or daughter 
compounds F7.1, F21.1, F27.2, F27.3 at the 
OX2R (n=5). Therefore, these compounds, 
including the highest affinity parent compound 
(P33) and derivative (F33.3) had no agonist 
activity and thus are antagonists at the human 
OX1 and OX2 receptors.  
Structure-Activity Relationship 
The lack of polar features in the binding 
pocket is echoed in the ligands. Therefore, it is 
challenging to develop a clear-cut SAR for 
them. There are many chemical solutions for a 
molecule to form favorable interactions with 
this receptor. In particular, apolar interactions 
are relatively tolerant towards subtle geometric 
changes. This tolerance can be seen here as 
several bulky substituents had very little effect 
of affinity.  
Looking at P33 and its derivatives (F33.1, 
F33.2, F33.3, [F33.4: no affinity], F33.5, 
F33.6, and F33.7), all these points are 
confirmed. This mini-series consists of the 
most potent parent P33 and daughter molecule 
(F33.3) with the highest number of active 
daughter compounds (six). The only polar 
interaction these molecules form is with 
Asn3246.55, yet the overall binding mode of 
P33 is not suvorexant-like (Figure 6 right). 
The daughters tell us that the position or 
existence of the halogens on the benzene rings 
are not important (F33.2 and F33.3 bind), but 
that more bulk in this region is not favorable 
(F33.1 is worse). There seems to be more space 
around the methyl-furane, however, as it can be 
replaced with bulkier groups (F33.6, F33.7). 
For these latter molecules, a more suvorexant-
like binding mode is conceivable. 
Interestingly, all the most active compounds 
show a double acceptor feature, which is 
absent in the weaker ligands. The most potent 
compound of this series, F33.3, might also be 
the only one truly capable of adapting a 
suvorexant-like conformation according to 
docking (Figure 6 left).  
For P7 and similar (F7.1, [F7.2: no 
affinity], F7.3, F7.4, [F7.5 and F7.6: no 
affinity], and F7.7), a slightly different picture 
Figure 6: Depictions of F33.3 (left) and P33 (right) showing poses of the most potent and the 
most OX2R selective compound, respectively. Compounds are shown in green sticks. Asn324
6.55 
and His3507.39 in orange sticks (bold and thin, respectively). Helix 7 was removed for clarity. 
Color code: C green, N blue, O red, S yellow, Cl dark green, F cyan. PDB code: 4S0V. 
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emerges. Compound P7 interacts with residues 
Glu21245.52 and Arg3286.59, both located at the 
entrance of the binding site and forming a lid, 
shielding it from bulk solvent. The derivatives 
are only bound to Asn3246.55. Of note, F7.7 
binds in an orientation reminiscent of a reverse 
suvorexant binding mode (Figure 7). Despite a 
certain difference in the overall layout, all of 
the compounds with affinity feature a 
pyrimidinone ring and a relatively apolar 
double ring system. 
Finally, as a negative example, we turn to 
parent compound P9. Although P9 has affinity 
for orexin receptors, none of the 12 derivatives 
showed much binding. This series also shows 
the perils of similarity searches, as several of 
the ligands would not be considered similar by 
a chemist. Yet, these seemed to interact 
favorably with the binding pocket in docking. 
F9.8 is the only compound with a similar 
“double lactam” cyclohexene ring and the only 
to show some effect. 
Overall, our docking screen showed that 
even for relatively featureless apolar binding 
pockets, ligands can be found in large 
databases based on shape complementarity 
(see Figure 4 for the ten most affine 
compounds found in this study). Interestingly, 
the scarcity of strong polar or even charge-
charge interaction possibilities did not hamper 
docking’s ability to find ligands, evident from 
the overall hit rate of 29%, which compares 
favorably with other studies on class A 
GPCRs. Several novel chemotypes were 
identified and might serve as seeds for further 
development. 
Discussion and conclusions  
Our unbiased docking screen (using the 
OX2R crystal structure) answers the three 
questions posed in the introduction. A metric 
that is often used as the figure of merit in a 
docking screen is the hit rate, defined as the 
percentage of all tested molecules that are 
    
  
Figure 7: Depictions of poses of P7 (left) and F7.7 (right), respectively. Compounds are shown in 
green sticks. Asn3246.55 and His3507.39 in orange sticks (bold and thin, respectively). Glu21245.52 
and Arg3286.59 in cyan sticks (bold and thin, respectively). Helix 7 was removed for clarity. Color 
code: C green, N blue, O red, S yellow, Cl dark green, F cyan. The protein is PDB code: 4S0V. 
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found to interact with the receptor. In this 
study, taking the hits from the parent and 
daughter screen into account, a hit rate of 29% 
was achieved in the CHO-OX2 cells, based on 
binding affinity. Despite the challenging nature 
of the binding pocket, with only few polar 
interactions sprinkled throughout, this puts the 
present screen in the same league as previous 
studies with polar or even charged features 
within the binding pockets. Docking itself thus 
does not seem to be hampered by this 
comparative scarcity of directional interactions 
in the OX2R. The hit rates of the daughter 
generation are almost the same as the parents’ 
rates, however. This might be because the 
similarity calculations were based on global 
similarities. A stricter similarity search, 
retaining the scaffolds of the parent 
compounds, might have produced higher hit 
rates.  
Secondly, we took a closer look at the 
predicted binding modes and compared them 
with the ones of suvorexant and SB-674042. 
The majority of molecules interact with very 
similar residues, predominantly Asn3246.55 and 
His3507.39. Interestingly, however, a few of 
them also formed interactions with Thr1112.61, 
a residue that differs in OX1R, where it is a 
serine (Ser1032.61). Despite this being a small 
deviation, such compounds might be starting 
points for selective orexin receptor antagonists 
(SORAs). On top of this, compound P22 forms 
a hydrogen bond with the backbone carbonyl 
of Pro1313.29, which has so far not been 
observed in any of the crystal structures. 
Lastly, this docking strategy has managed 
to identify several scaffolds that can be 
considered novel by common chemoinformatic 
criteria. Among them are compound P27, 
whose ECFP4 Tanimoto similarity to its 
closest match amongst any known ligands of 
OX2R is only 0.237 (median similarity of 
0.115). Two additional compounds, F33.2 and 
F7.4, show also distant closest matches and 
low maximum similarities of 0.241 (median of 
0.124) and 0.254 (median of 0.121), 
respectively. In total, 52 compounds that show 
some affinity in our assay, had an ECFP4 
Tanimoto similarity to their closest neighbors 
of 0.45 or less, and 22 with a similarity value 
of 0.30 and less, commonly regarded as a 
threshold indicating dissimilarity (ECFP4 
Tanimoto similarity values and ROCS 
TanimotoCombo scores can be found in the 
Supplementary Information [Table S 3 and 
Table S 5]).  
A key question for future investigations is 
whether these scaffolds can easily be 
derivatized. To answer this question, the 
composition was analyzed with the PINGUI 
(15) toolbox, which we have developed earlier. 
Each of the compounds shows a facile 
synthetic breaking point, yielding fragments of 
a size that is frequently occurring in building 
block databases. The number of applicable 
reactions to fragments of our hits after their 
retrosynthetical decomposition ranges from 
two (F21.3) to nine (P18) (Table S 6). It is 
likely that also the derivatives will show 
affinity, as we have already exhausted existing 
chemical space through SAR-by-catalog. In 
particular compound P33 seems very 
promising, as five of its daughter compounds 
(F33.1-3, F33.6 and F33.7) also show binding 
to the receptor. Our analysis found 103 
retrosynthetical disconnections. Four unique 
reactions can be applied to the resulting 
fragment set. It has to be noted that P33 shares 
some moieties with the known ligands EMPA 
and SB-649868. Based on our SAR 
considerations and our experience from similar 
projects (15,16) we are convinced that there is 
room for diversity around the common rings, 
however. 
By way of better characterization, we also 
tested our compounds against the OX1R, 
despite the fact that we never made a prediction 
about selectivity. Not unexpectedly, most of 
the compounds behave as DORAs. In fact, our 
OX2R-focused docking produced five 
compounds with a measurable affinity 
selectivity between OX2R and OX1R, but only 
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up to a maximum selectivity of 5-fold (a ΔpKi 
of 0.6). Although measurable, these values are 
low and at the detection limit of the assay. At 
the same time, OX2R-selective compounds are 
generally regarded as preferable for the 
treatment of insomnia, as they carry lower risks 
of OX1R-mediated side effects, such as 
compulsive behavior and substance misuse 
disorders. (17) 
Would this be different if we had docked 
to both subtypes? In order to answer this 
question, we did a dual docking as described 
before. (11) Briefly, the same small molecule 
dataset was docked to both the OX1R and the 
OX2R. For the OX1R, the X-ray structure with 
PDB ID 4ZJ8 (18) was used and prepared in an 
identical fashion as its OX2R counterpart. After 
docking, molecules were reranked in order to 
favor molecules that would display the desired 
selectivity. (11) The molecules populating the 
top 500 ranks of this docking were all distinct 
from the ones of the original docking against 
the OX2R, and, therefore, there was also no 
overlap between the sets of assayed molecules. 
However, even with this differential docking, 
we did not find ligands with more than a ΔpKi 
of 0.5. The data for these molecules is 
presented in Table 3. It thus stands to reason 
that this featureless binding pocket presents a 
case where standard docking protocols run in 
high-throughput mode do not discriminate well 
enough in order to predict selectivity between 
the two orexin receptor subtypes. As we have 
shown recently, this is different for dedicated 
more precise docking calculations used to 
optimize ligand selectivity, driving it towards 
higher OX1R affinity. (19) 
In summary, our in silico screen yielded 
several compounds with potential for further 
development as orexin receptor ligands and 
shed light on possible alternative interaction 
patterns that can be exploited in future 
screening and optimization work.   
Experimental Section 
Receptor preparation 
The crystal structure of the OX2R liganded 
by suvorexant (PDB code 4S0V) (5) was 
prepared using the MOE software suite. (20) 
Briefly, i) all water molecules, metal ions, 
precipitants and lipids were removed. ii) The 
fusion protein glycogen synthase from P. 
abysii was cleaved from the receptor at amino 
acids Lys2946.25 and Gln2545.69. iii) Loop 
breaks and fusion protein cleavage sites were 
capped with methylamine and acetyl at C- and 
N-termini, respectively. iv) Hydrogen atoms 
were added, and the protonation states of 
titratable amino acids were assigned using 
MOE’s Protein Preparation subroutines (pH-
value 7.4, temperature 300 K). Protonation 
states of histidines and rotamers of head groups 
of glutamines and asparagines were visually 
inspected and adjusted according to their 
protein environment. 
Database generation 
The DrugsNow subset of the ZINC 
database (21) was downloaded as SMILES 
strings (7.377 million entries). The subset was 
split into batches of 10000 molecules (738 
batches). Each batch was submitted to 
OpenEye’s OMEGA program for conformer 
generation. (22) For each molecular entity, a 
maximum number of 400 conformers was 
generated. The energy window parameter was 
set to 10.0 and the rms (root mean square 
deviation of conformer coordinates) parameter 
to 0.5. The “strict” flag was set to “true” 
ensuring that molecules without fully specified 
stereochemistry were discarded. A total of 
1.726 billion conformers were generated. For 
docking with DOCK, the ZINC LeadLike 
subset was downloaded in flexibase format 
(3.987 million entries) and used as-is (Figure 
2A). 
Docking 
Docking was performed using OpenEye’s 
HYBRID program. (23,24) The ensemble of 
conformations of each molecule was overlaid 
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with the co-crystallized ligand (suvorexant) in 
order to determine the best suited conformer 
for the following exhaustive docking. The 
method for overlaying conformers is built 
directly into the HYBRID engine and is based 
on the same methodology as implemented in 
the OEChem API and the ROCS application. 
(25) For the actual docking step – translational 
and rotational optimization of a compound 
conformer within the binding site of the protein 
– HYBRID scores for a given protein-ligand 
complex were calculated based on the shape 
and electrostatic complementarity of the ligand 
and the protein’s binding site. Shape and 
electrostatic features are represented by 
Gaussian potentials. During optimization, the 
overlap between ligand and protein features is 
maximized. After docking, the 100 best-scored 
poses were extracted from each batch and 
aggregated into one sorted scoring list (73800, 
entries, corresponds to best scored percentile of 
the entire docking run). 
The ZINC LeadLike subset was docked 
with DOCK. (26) Briefly, molecules were 
placed using guiding points inside the pocket 
that had been derived from suvorexant bound 
to the OX2R in the crystal structure (PDB code 
4S0V) (5). 
All docking scores can be found in the 
supplementary information (Table S 4). 
Molecules were purchased from various 
vendors, as listed in Table S2. Purity of all 
ligands is ≥ 95 %, as determined by LC/MS 
and different methods employed by the 
vendors. 
Post-processing 
The scoring list of ~74000 poses was 
treated in three different ways: i) left 
unchanged (sorted by HYBRID score), ii) 
rescored by DSX (27) and iii) submitted to a 
rigid body optimization procedure using 
OpenEye’s SZYBKI program. (28) During this 
optimization process, the atoms of the receptor 
were kept fixed at their crystallographic 
positions, while the rotational, translational 
and torsional degrees of freedom of each pose 
were optimized using a Poisson-Boltzmann 
solvation model. The resulting poses were 
sorted by the SZYBKI ligand-protein 
interaction energy. 
From each of the scoring lists (HYBRID, 
DSX and SZYBKI), a slice of 2000 poses was 
extracted and subjected to visual inspection in 
order to remove those that form improbable 
interactions that are not sufficiently penalized 
by present-day scoring functions. In addition, 
the 500 best-scored poses from the docking run 
with DOCK were added to the visual 
inspection. Selected compounds were acquired 
from their respective vendors and analyzed 
pharmacologically. Parent generation of 
compounds are denoted with a capital P 
(Figure 2B). 
Similarity screen 
Several experimentally validated 
compounds from the parent generation (both 
with and without affinity against the receptor) 
were used as queries for the retrieval of close 
analogs by a fingerprint-based similarity 
screen: For each of the nine hits (P7, P9, P21, 
P22, P27, P31, P32, P33 and P35), the 30 
nearest neighbors were retrieved from the three 
2000 entries-long slices (HYBRID, DSX and 
SZYBKI [Figure 2B]). The retrieved poses 
were all subjected to optimization with 
SZYBKI. The resulting geometries were 
visually inspected and the selected compounds 
were acquired from their respective vendors 
and analyzed pharmacologically (daughter 
generation of compounds denoted with a 
capital F) (Figure 2C).  
Experimental validation 
Materials 
3H-SB674042 was from Metis 
Laboratories (New York, USA) and 3H-EMPA 
was from Novandi Chemistry (Södertälje, 
Sweden). Fluo-4AM and pluronic F-127 were 
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from Invitrogen (Oregon, USA). Orexin A, 
SB334867, SB674042, JNJ10397049 and 
EMPA were from Tocris Life Sciences 
(Avonmouth, UK). Suvorexant was from 
Selleckchem (Houston, USA). Gibco fetal 
bovine serum was from Fischer Scientific 
(Loughborough, UK). All other reagents were 
from Sigma Aldrich (Poole, UK). 
Cell-culture 
CHO cells stably expressing either the 
human OX1 or OX2 receptor (originally a gift 
from Heptares, UK) were secondarily 
transfected with an SRE-luciferase reporter 
gene and stable clones selected by dilution 
cloning to create CHO-OX1 and CHO-OX2 
stable cell lines. Cells were grown in 
Dulbecco’s modified Eagle’s medium nutrient 
mix F12 (DMEM/F12) containing 10 % fetal 
calf serum (FCS) and 2 mM L-glutamine in a 
37°C humidified 5 % CO2: 95 % air 
atmosphere. 
Whole cell 3H-radioligand binding 
The affinity of compounds for the OX1 and 
OX2 receptors were determined from whole 
cell binding studies. Experiments were 
conducted on confluent cells in white-sided 
96-well view plates as previously described 
(2 hour 37°C incubation with radioligand and 
competing ligand in 200 µl serum-free media, 
Baker 2005). A 7-point concentration response 
curve (each point in triplicate) was examined 
for each ligand in each experiment. Suvorexant 
(10 μM) was used to define non-specific 
binding. The affinity of the radioligands has 
previously been determined as 4.65 nM for 3H-
SB674042 in the CHO-OX1 cells and 7.86 nM 
for 3H-EMPA in the CHO-OX2 cells. (14) 
Cells were inspected under a light microscope 
to ensure they were still present after the 2-
hour incubation, both before and after the 
wash. In a few cases, high concentrations 
(100µM) of competing ligand caused the cells 
to round up and be washed off the plates. These 
concentrations were excluded from the 
analysis. 
The IC50 value of competing ligands was 
determined from a sigmoidal response curve 
(plotted in Prism 7) where the IC50 is the 
concentration required to inhibit 50 % of the 
specific binding of the 3H-radioligand, [A] is 
the concentration of the competing ligand. 




The Ki values for the competing ligands was 
then determined from the IC50 values using 
Cheng-Prusoff equation where [L] is the 
concentration of radioligand in that experiment 
and LKD is the KD value of the radioligand (as 







Intracellular calcium release 
Calcium measurements were made using a 
Flexstation 3 at 37°C. Cells, seeded into black 
96-well view plates, were loaded with Fluo-
4AM / pluronic-F127 in serum-free media 
containing probenecid (25 mM) for 45 minutes 
at 37°C. Cells were washed with 200 μl 
HEPES buffered saline (HBS, containing 2 μM 
CaCl2) per well, before a further 80 µl HBS 
was then added to each well.  Ligands were 
diluted in HBS to 5 times final concentration in 
round bottomed 96-well compound plates. 
During the experiment, the Flexstation robotics 
added 20 µl of ligand from the compound plate 
into the existing 80 µl HBS in the cell plate 
(1:5 dilution in well). Ionomycin (10 µM) and 
orexin A (1 μM) were used as positive controls 
each plate in each experiment. Calcium 
mobilization was followed for 120 seconds and 
data were plotted as the maximum value 
obtained for calcium mobilization over the 
basal value obtained for that well before the 
addition of ligand. 
A sigmoidal concentration response curve 
was fitted to the data (using Prism 7) where 
Emax is the maximum response, [A] is the 
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agonist concentration and EC50 is the 
concentration of agonist that produces 50 % of 






Tabular data as PDF files containing 
compound structures, SMILES strings, and 
supplier information; Tanimoto fingerprint 
similarities, ROCS TanimotoCombo scores, 
docking scores; and retrosynthetical analysis. 
Predicted complex structures for all molecules 
are provided in PDB format. 
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Table 1: pKi values, obtained for five known orexin ligands and the initial 43 compounds 
identified from the primary docking screen, from whole cell binding studies as determined from 
using 3H-SB674042 (CHO-OX1 cells) and 
3H-EMPA (CHO-OX2 cells). Values are mean ± sem 
from n separate experiments. 
app = apparent Ki value. Here, the maximal achievable concentration of competing ligand was not 
able to fully inhibit the radioligand specific binding. In cases where greater than 50% specific 
binding was inhibited, an apparent Ki value is given, assuming that if a greater concentration of 
ligand were possible, full inhibition of specific binding would have occurred.  
 
IC50 > 100 µM. Here, inhibition of specific binding by the competing ligand was less than 50% so 
an IC50 value, and therefore Ki value, could not be calculated. The IC50 must therefore have been 
greater than the maximum concentration of competing.  
 
ep = early plateau. Some ligands did not fully inhibit radioligand binding but appeared to reach an 
early plateau. Here increasing concentrations of competing ligand reached a maximum inhibition 
that was less than that achieved by suvorexant (similar to that seen in Proudman and Baker 2018 
(14)). In these cases, an apparent Ki value is given for the partial inhibition of specific binding. 
The percentage of specific binding inhibited was 79.2 ± 3.3% for P27 and 63.7 ± 2.1% for P35 in 
the CHO-OX2 cells. 
 
ID CHO-OX1    CHO-OX2  
 pKi n  pKi n 
suvorexant 8.51 ± 0.06 13  8.53 ± 0.03 17 
SB334867 7.38 ± 0.04 5  5.43 ± 0.08 4 
SB674042 8.41 ± 0.08 5  6.70 ± 0.11 3 
JNJ10397049 5.87 ± 0.02 5  8.18 ± 0.14 4 
EMPA 5.35 ± 0.05 6  8.17 ± 0.05 5 
      
P1 No binding 4  No binding 4 
P2 No binding 4  No binding 4 
P3 No binding 4  IC50 > 100 µM 4 
P4 IC50 > 100 µM 4  No binding 4 
P5 No binding 4  IC50 > 100 µM 4 
P6 No binding 4  No binding 4 
P7 4.48 ± 0.08app 4  4.57 ± 0.10app 5 
P8 No binding 3  IC50 > 100 µM 4 
P9 4.85 ± 0.05app 9  5.40 ± 0.06app 9 
P10 IC50 > 100 µM 4  IC50 > 100 µM 4 
P11 No binding 4  No binding 4 
P12 4.75 ± 0.09 4  4.21 ± 0.02app 4 
P13 IC50 > 100 µM 4  4.22 ± 0.03
app 4 
P14 No binding 4  No binding 4 
P15 IC50 > 100 µM 4  4.17 ± 0.01
app 4 
P16 No binding 3  No binding 4 
P17 IC50 > 100 µM 4  IC50 > 100 µM 4 
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ID CHO-OX1    CHO-OX2  
P18 4.67 ± 0.11app 4  IC50 > 100 µM 4 
P19 IC50 > 100 µM 4  IC50 > 100 µM 4 
P20 No binding 4  No binding 4 
P21 4.36 ± 0.05app 4  4.23 ± 0.03app 5 
P22 IC50 > 100 µM 4  4.49 ± 0.05
app 5 
P23 No binding 4  No binding 4 
P24 IC50 > 100 µM 4  IC50 > 100 µM 4 
P25 No binding 4  No binding 4 
P26 IC50 > 100 µM 4  IC50 > 100 µM 4 
P27 4.81 ± 0.05 4  5.07 ± 0.03ep 5 
P28 No binding 4  IC50 > 100 µM 4 
P29 No binding 4  No binding 4 
P30 No binding 4  IC50 > 100 µM 4 
P31 IC50 > 100 µM 3  IC50 > 100 µM 4 
P32 No binding 4  No binding 5 
P33 4.93 ± 0.03 8  5.55 ± 0.02 9 
P34 IC50 > 100 µM 4  4.69 ± 0.02
app 4 
P35 5.27 ± 0.08 9  5.27 ± 0.06ep 10 
P36 No binding 4  No binding 4 
P37 IC50 > 100 µM 4  No binding 4 
P38 IC50 > 100 µM 4  IC50 > 100 µM 4 
P39 No binding 4  No binding 4 
P40 IC50 > 100 µM 4  No binding 4 
P41 No binding 9  No binding 9 
P42 No binding 4  No binding 4 
P43 IC50 > 100 µM 4  IC50 > 100 µM 4 
 
Table 2: pKi values, obtained for parent and daughter compounds from whole cell binding studies 
as determined from using 3H-SB674042 (CHO-OX1 cells) and 
3H-EMPA (CHO-OX2 cells). 
Values are mean ± sem from n separate experiments. 
app = apparent Ki value (as above, greater than 50% specific binding was inhibited, so an apparent 
Ki value is given, assuming that if a greater concentration of ligand were possible, full inhibition 
of specific binding would have occurred). Where inhibition of specific binding was less than 50%, 
IC50 > concentration of maximum concentration of competing ligand used is given.  
 
ep = early plateau (as above, competing ligand appeared to a plateau whereby increasing 
competing ligand concentration could not fully inhibit the radioligand. An apparent Ki value is 
given for the partial inhibition of specific binding. The percentage of specific binding inhibited 
was 57.2 ± 2.2% for F7.3, 52.2 ± 2.2% for F9.8, 64.6 ± 3.5% for F32.2, and 58.7 ± 4.7% for F35.7, 
respectively, in the CHO-OX1. In the CHO-OX2 cells, the percentage of specific binding inhibited 




ID CHO-OX1   CHO-OX2  
 pKi n  pKi n 
P7 4.48 ± 0.08app 4  4.57 ± 0.10app 5 
F7.1 4.68 ± 0.04 4  4.48 ± 0.03app 4 
F7.2 No binding  5  No binding  5 
F7.3 5.90 ± 0.10ep 5  5.83 ± 0.05ep 5 
F7.4 4.83 ± 0.07 5  4.89 ± 0.02 5 
F7.5 No binding  5  No binding  5 
F7.6 IC50 > 100 µM 5  IC50 > 100 µM 5 
F7.7 IC50 > 100 µM 5  4.34 ± 0.06
app 5 
F7.8 No binding  5  No binding  5 
      
P9 4.85 ± 0.05 9  5.40 ± 0.06 9 
F9.1 IC50 > 100 µM 5  IC50 > 100 µM 5 
F9.2 No binding  5  No binding  5 
F9.3 4.49 ± 0.04 app 5  IC50 > 100 µM 5 
F9.4 No binding  5  No binding  5 
F9.5 No binding  5  No binding  5 
F9.6 IC50 > 100 µM 5  IC50 > 100 µM 5 
F9.7 No binding  5  No binding  5 
F9.8 5.11 ± 0.10ep 5  4.97 ± 0.06ep  5 
F9.9 IC50 >-5 5  IC50 >-5 5 
F9.10 No binding  5  No binding  5 
F9.11 No binding  5  No binding  5 
F9.12 No binding  5  No binding  5 
      
P21 4.36 ± 0.05app 4  4.23 ± 0.03app 5 
F21.1a 4.83 ± 0.09 4  4.44 ± 0.01app 4 
F21.2 No binding 3  No binding 4 
F21.3b No binding 4  IC50 > 100 µM 4 
F21.4 IC50 > 100 µM 4  IC50 > 100 µM 4 
      
P22 IC50 > 100 µM 4  4.49 ± 0.05
app 5 
F22.1b No binding 4  IC50 > 100 µM 4 
      
P27 4.81 ± 0.05 4  5.07 ± 0.03ep 5 
F27.1 No binding 4  IC50 > 100 µM 4 
F27.2 IC50 > 100 µM 4  4.39 ± 0.05
app 4 
F27.3 4.82 ± 0.04 4  4.49 ± 0.01app 4 
F27.4 No binding 4  No binding 4 
F27.5 No binding 4  No binding 4 
F27.6 IC50 > 100 µM 4  4.23 ± 0.05
app 4 
F27.7 No binding 3  No binding 4 
F27.8 No binding 3  No binding 4 
      
P31 IC50 > 100 µM 3  IC50 > 100 µM 4 
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ID CHO-OX1   CHO-OX2  
F31.1 No binding 5  IC50 > 100 µM 4 
      
P32 No binding 4  No binding 5 
F32.1 IC50 > 100 µM 4  4.22 ± 0.05
app 4 
F32.2 5.10 ± 0.01ep 4  4.98 ± 0.06ep 4 
      
P33 4.93 ± 0.03 8  5.55 ± 0.02 9 
F33.1b 4.83 ± 0.09 4  4.44 ± 0.01app 4 
F33.2 4.77 ± 0.02 4  5.53 ± 0.05 4 
F33.3 5.49 ± 0.05 4  6.18 ± 0.03 4 
F33.4 No binding 5  4.27 ± 0.03app 4 
F33.5 IC50 > 100 µM 4  IC50 > 100 µM 4 
F33.6 5.05 ± 0.12 4  5.50 ± 0.05 4 
F33.7 5.45 ± 0.13 4  5.50 ± 0.02 4 
      
P35 5.27 ± 0.08 9  5.27 ± 0.06ep 10 
F35.1 IC50 > 100 µM 5  IC50 > 100 µM 5 
F35.2 No binding  5  No binding  5 
F35.3 No binding  5  No binding  5 
F35.4 No binding  5  No binding  5 
F35.5 No binding  5  No binding  5 
F35.6 4.61 ± 0.03app 5  4.38 ± 0.08app 5 
F35.7 5.29 ± 0.05ep 5  5.19 ± 0.07ep 5 
F35.8 IC50 > 100 µM 5  IC50 > 100 µM 5 
F35.9 IC50 > 100 µM 5  IC50 > 100 µM 5 
F35.10 No binding  5  No binding  5 
F35.11 No binding  5  No binding  5 
F35.12 No binding  5  No binding  5 
F35.13 No binding  5  No binding  5 
F35.14 No binding  5  No binding  5 
F35.15 No binding  5  No binding  5 
F35.16 No binding  5  No binding  5 
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Table 3: pKi values, obtained for compounds originating from differential docking from whole 
cell binding studies as determined from using 3H-SB674042 (CHO-OX1 cells) and 
3H-EMPA 
(CHO-OX2 cells). Values are mean ± sem from n separate experiments. 
aThe compound 
corresponding to F21.1 and F33.1 was found twice in the similarity searches for the parent 
compounds P21 and P33, respectively. Hence, we report it in both family trees, but count it only 
once for the hit rate. bThe compound corresponding to F21.3 and F22.1 was found twice in the 
similarity searches for the parent compounds P21 and P22, respectively. Hence, we report it in 
both family trees. 
ID CHO-OX1   CHO-OX2  
 pKi n  pKi n 
S1.1 No binding  5  No binding  5 
S1.2 No binding  5  No binding  5 
S1.3 No binding  6  No binding  6 
S1.4 IC50 > 100 µM 5  IC50 > 100 µM 5 
S1.5 IC50 > 100 µM 5  IC50 > 100 µM 5 
S1.6 4.83 ± 0.04 5  4.64 ± 0.01 5 
S1.7 No binding  5  No binding  5 
S2.1 No binding 5  No binding  5 
S2.2 IC50 > 100 µM 5  4.28 ± 0.04 5 
S2.3 IC50 > 100 µM 5  IC50 > 100 µM 5 
S2.4 No binding  5  No binding  5 
S2.5 No binding  5  No binding  5 
S2.6 No binding  5  No binding  5 
S2.7 5.38 ± 0.07 5  5.80 ± 0.02 5 
S2.8 IC50 > 100 µM 5  IC50 > 100 µM 5 
S2.9 No binding  5  No binding  5 
S3.1 No binding  5  No binding  5 
S3.2 No binding  5  IC50 > 100 µM 5 
S3.3 No binding  5  No binding  5 
S3.4 IC50 > 100 µM 5  4.40 ± 0.08 5 
S3.5 4.47 ± 0.10 5  4.56 ± 0.03 5 
S3.6 No binding  5  No binding  5 
S3.7 IC50 > 100 µM 5  IC50 > 100 µM 5 
S3.8 4.61 ± 0.08 5  4.82 ± 0.06 5 
S3.9 No binding  5  No binding  5 
 
